Hao, ScarlettMitsakos, AnastasiosIrish, WilliamTuttle‐Newhall, Janet ElizabethParikh, Alexander A.Rebecca A., Snyder2022-08-042022-08-042022-03-10http://hdl.handle.net/10342/10979This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.Background and Methods:Racial and socioeconomic disparities in receipt ofadjuvant chemotherapy affect patients with pancreatic cancer. However, differencesin receipt of neoadjuvant chemotherapy among patients undergoing resection arenot well‐understood. A retrospective cross‐sectional cohort of patients withresected AJCC Stage I/II pancreatic ductal adenocarcinoma was identified fromthe National Cancer Database (2014–2017). Outcomes included receipt ofneoadjuvant versus adjuvant chemotherapy, or receipt of either, defined asmultimodality therapy and were assessed by univariate and multivariate analysis.Results:Of 19 588 patients, 5098 (26%) received neoadjuvant chemotherapy, 9624(49.1%) received adjuvant chemotherapy only, and 4757 (24.3%) received nochemotherapy. On multivariable analysis, Black patients had lower odds ofneoadjuvant chemotherapy compared to White patients (OR: 0.80, 95% CI:0.67–0.97) but no differences in receipt of multimodality therapy (OR: 0.89, 95%CI: 0.77–1.03). Patients with Medicaid or no insurance, low educational attainment,or low median income had significantly lower odds of receiving neoadjuvantchemotherapy or multimodality therapy.Conclusions:Racial and socioeconomic disparities persist in receipt of neoadjuvantand multimodality therapy in patients with resected pancreatic adenocarcinoma.Discussion:Policy and interventional implementations are needed to bridge thecontinued socioeconomic and racial disparity gap in pancreatic cancer care.enhealthcare disparitymultimodal treatmentneoadjuvant chemotherapy,pancreas cancersocioeconomic factorsArticle10.1002/jso.26859